Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 453

Document Document Title
WO/2020/243155A1
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an es...  
WO/2020/150417A3
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2020/150417A2
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2020/091054A1
The invention provides a novel production method for an isoquinoline-6-sulfonamide derivative that is useful as a medicinal drug, and also provides an intermediate for use in the method. The invention is the 1,4-diazocane compound repres...  
WO/2019/226925A1
Disclosed are cationic lipids which are compounds of Formula (I), (II), (III), (IV), (V), or (VI). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal d...  
WO/2019/075259A1
The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1,...  
WO/2018/233326A1
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...  
WO/2018/183198A1
Methods for making an arylomycin ring of formula t or salts or solvates thereof, wherein R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R5, R10 and Pg1 are as defined herein.  
WO/2018/149419A1
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential pro...  
WO/2018/070773A1
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure can provide a low driving voltage and excellent luminous efficiency by comprising a specific combinat...  
WO/2018/043829A1
Provided are a compound represented by a specific formula, a core-shell dye comprising a core comprising the compound and a shell enclosing the core, a photosensitive resin composition comprising the core-shell dye, and a color filter ma...  
WO/2017/218922A8
Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.  
WO/2017/218922A3
Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.  
WO/2017/173048A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin- related disorders.  
WO/2017/156471A1
The disclosure provides for compounds having immunoproteasome inhibitory activity, and pharmaceutical compositions made thereof. The disclosure further provides for the use of the compounds and compositions in treating various diseases a...  
WO/2017/156074A1
The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or medi...  
WO/2017/116272A1
The invention relates to the field of the organic chemistry and, in particular to a method for preparing a compound of formula (I) or (II), and/or a mixture of isomers thereof, wherein R is -Alk, -AlkN(Alk)2, -AlkN(Ar)2, -AlkNAlkAr, -Alk...  
WO/2017/084630A1
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential pro...  
WO/2017/084629A1
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential pro...  
WO/2017/003188A1
The present invention relates to: a novel compound which has an outstanding luminescent ability; and an organic electroluminescent element having improved properties including high luminous efficiency, low drive voltage and long lifespan...  
WO/2016/118278A3
The present application for patent discloses a composition of matter comprising: comprising a solvent; and an ester having a chemical structure chosen from (I), (II), or (III); wherein X and Y are the same or different, wherein at least ...  
WO/2016/193482A1
Processes for preparation of 7-chloro-1-methyl-5-phenyl-1,5-dihydro- benzo[b][1,4]diazepine-2,4-dione (Clobazam) are provided. The present invention also relates to the novel intermediates and its use in preparation of clobazam.  
WO/2015/188107A8
Synthesis of novel and unique PAMAM (poly-amidoamine) polymers. PAMAM polymers can be grown by systematic alternation between ethylenediamine (EDA) and methacrylate. By taking advantage of the alternating terminal ends, successive genera...  
WO/2015/188107A1
Synthesis of novel and unique PAMAM (poly-amidoamine) polymers. PAMAM polymers can be grown by systematic alternation between ethylenediamine (EDA) and methacrylate. By taking advantage of the alternating terminal ends, successive genera...  
WO/2015/175770A1
Largazole analogues, methods of making the same, and methods of using the same, are described.  
WO/2015/157057A1
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.  
WO/2014/201073A9
The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.  
WO/2015/070204A1
Provided herein are compounds of the formula (I) : as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containin...  
WO/2014/201073A1
The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.  
WO/2014/183015A1
Compositions are provided for selectively inhibiting bacterial proteasome. Also provided are methods for assaying the compositions, methods for treating bacterial infection, and methods for inducing apoptosis in tumor cells using the com...  
WO/2014/081886A1
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type (1) signal peptidase (SpsB), an essential p...  
WO/2014/048692A1
The present invention relates to a method for producing metathesis products comprising contacting metathesis starting materials under metathesis conditions with a metathesis catalyst, wherein the metathesis catalyst is employed in an amo...  
WO/2014/008204A3
Disclosed herein are novel structures of proteasome inhibitors and methods for synthesizing and use thereof, including novel structures of proteasome inhibitors, such as syrbactins and its analogs, and methods for synthesizing them and u...  
WO/2013/181584A3
The present disclosure pertains to the discovery of a new family of "first in class" small molecular inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA for use as therapeutics in the management of chronic HBV. Pro...  
WO/2013/188750A3
The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors.  
WO/2013/188750A2
The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors.  
WO/2012/167171A2
The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.  
WO/2012/114342A1
The present invention provides soluble complexes of flumazenil, methods for the preparation thereof, pharmaceutical compositions comprising same and use of said compositions for alleviating or counteracting the various types of hypersomn...  
WO/2012/070015A9
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...  
WO/2012/070015A1
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...  
WO/2012/051413A1
Provided are methods for reversing the effects of agents used for muscular immobilization and/or loss of consciousness and/or loss of pain perception. The method comprises administering a composition comprising acyclic CB[n]-type compoun...  
WO/2011/137190A1
Embodiments of the invention provide a tetraamido macrocyclic ligand catalytic activator bound to a carbon containing support. When combined with an oxidant, such as a peroxy compound, the carbon supported catalytic activator is a long-l...  
WO/2011/069045A3
The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.  
WO/2011/050068A3
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The inv...  
WO/2011/107248A1
The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present inv...  
WO/2011/076674A1
The invention relates to polymers (P) of amides, imides, amides-imides or their derivates. The polymer (P) comprising recurring units (I) of one or more structural formula(e):-A-B-C-D- (I), wherein, A and C, identical or different from e...  
WO/2011/069045A2
The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.  
WO/2010/081731A4
The present invention relates to syringolin A derivatives, the use of the syringolin A derivatives for prophylaxis and treatment of neurodegenerative diseases and proliferative diseases such as cancer, pharmaceutical compositions contain...  
WO/2011/058193A1
The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound ...  
WO/2011/050068A2
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The inv...  

Matches 1 - 50 out of 453